Infection of adherent primary monocytes with HIV-lBa.L is significantly suppressed in the presence of human saliva. By reverse transcriptase (RT) levels, saliva, although present for only 1 h during monocyte viral exposure, inhibited HIV-1 infectivity for 3 wk after infection, whereas human plasma and synovial fluid failed to inhibit HIV-1 infectivity. Antiviral activity was identified in the saliva soluble fraction, and to determine the factor (s) responsible, individual saliva proteins were examined. Of those proteins examined, only secretory leukocyte protease inhibitor (SLPI) was found to possess anti-HIV-1 activity at physiological concentrations. SLPI anti-HIV-1 activity was dose dependent, with maximal inhibition at 1-10 gg/ml (> 90% inhibition of RT activity). SLPI also partially inhibited HIV-111B infection in proliferating human T cells. SLPI appears to target a host cell-associated molecule, since no interaction with viral proteins could be demonstrated. However, SLPI anti-HIV-1 activity was not due to direct interaction with or downregulation of the CD4 antigen. Partial depletion of SLPI in whole saliva resulted in decreased anti-HIV-1 activity of saliva. These data indicate that SLPI has antiretroviral activity and may contribute to the important antiviral activity of saliva associated with the infrequent oral transmission of HIV-1. (J. Clin. Invest. 1995. 96:456-464.)
Introduction
The virtual absence of oral transmission of HIV-1 (1) (2) (3) (4) and reports of antiviral activity in the saliva of both healthy (5) (6) (7) (8) (9) and HIV-1-infected (7) individuals suggest the presence of a factor or factors in saliva that can inhibit HIV-1 infection. Although the source(s) and mechanism for this activity remain A portion of these results was presented at the 2nd National Conference on Human Retroviruses and Related Infections sponsored by the American Society for Microbiology in Washington, D.C. on 29 January through 2 February 1995 and the Keysone Symposia on Molecular and Cellular Biology, HIV Pathogenesis in Keystone, CO on [17] [18] [19] [20] [21] [22] [23] April poorly understood, aggregation of HIV-1 by large molecular weight molecules (mucins, etc.) in the saliva has been implicated (8, 10, 11) and is consistent with the HIV-1 particle aggregation and entrapment by saliva observed ultrastructurally on small pore filters (12, 13) . Although virus aggregation by saliva mucins may play a role in the anti-HIV-1 effect of saliva, additional evidence for a soluble anti-HIV-1 activity has been reported (8, 11, 13) . Moreover, significant anti-HIV-1 activity may be found in parotid gland secretions, which are purely serous and contain no mucins and do not appear to aggregate HIV-1 particles ( 13, 14) . Therefore, it has been postulated that there are at least two mechanisms present in saliva that may contribute to antiviral activity in vitro. One of these is due to physical entrapment of the viral particles; the other is due to inhibitory activity by an unknown soluble factor(s).
Identification and characterization of the natural anti-HIV-1 agent(s) present in saliva may have significant implications. The anti-HIV-1 activity present in saliva does not appear to be due to a broad-spectrum antiviral agent, since some infectious viruses, such as cytomegalovirus, may be cultured from human saliva (6, 12) . The anti-HIV-1 activity appears to be specific to saliva because other body fluids, such as cerebrospinal fluid and urine (10), are devoid of anti-HIV-1 activity. The examination of saliva collected from individual salivary glands precludes the possibility of the presence of a large number of blood cells, bacteria, or food particles in the secretions and therefore their contributing to this inhibitory activity (6, 7, 13) .
To define this natural HIV-1 inhibitor, saliva secretion fractions and purified salivary proteins were examined for their ability to inhibit HIV-1 infection in an in vitro assay system using adherent human monocytes. Primary monocytes serve as host cells of HIV-1 in vivo, contribute to the pathology of AIDS, and are important targets for antiviral therapy (15) (16) (17) (18) (19) . These cells were infected with HIV-1 in the presence or absence of saliva and/or its constituents. Using this assay system, we have identified secretory leukocyte protease inhibitor (SLPI)' as a saliva-derived factor possessing significant anti-HIV-1 activity. We demonstrate here that the antiinfectivity action of SLPI does not appear to be at the level of HIV-1 binding, nor does SLPI inhibit reverse transcriptase (RT) or HIV-1 protease. Rather, its target may be a host cell-associated molecule. Based on its potent antiviral activity, SLPI, a 12-kD seine protease 1 . Abbreviations used in this paper: EDC, N-ethyl-N'-(3-diethylaminopropyl)-carbodiimide; HNE, human neutrophil elastase; HRP, histidine-rich peptide; IL-2R, IL-2 receptor; GSH, glutathione; NHS, Nhydroxysuccinimide; PLSD, protected least significant difference; PRP, proline-rich peptide; RT, reverse transcriptase; SLPI, secretory leukocyte protease inhibitor; sCD4, soluble CD4; TCID50, tissue culture infectious dose.
inhibitor (20) , may play a role in preventing oral infection and/ or transmission of HIV-1.
Methods
Monocyte isolation and culture. PBMC, obtained by leukapheresis (Department of Transfusion Medicine, National Institutes of Health), were separated from granulocytes by fractionation on Ficoll-Hypaque (Pharmacia Diagnostics AB, Stockholm, Sweden). PBMC were then separated by countercurrent centrifugal elutriation, as previously described (21) . By this method, 85-95% pure monocytes are obtained (21) . Monocytes were diluted to 2-4 x 106 cells per ml in DME (BioWhittaker, Walkersville, MD) with 2 mM L-glutamine and 50 ,ug/ml gentamicin and plated at 2 ml per well in glass two-well chamber slides (Nunc, Inc., Naperville, IL). After adherence (overnight, 370C, 5% C02), 10% human AB -serum (Advanced Biotechnologies Inc., Columbia, MD) was added to the culture medium. Cells were cultured from 10-14 d before being infected with HIV-1.
Reagents assayedfor anti-HIV-I activity. Whole human saliva (unstimulated) was collected into polypropylene tubes and centrifuged at 3,000 g for 15 min. For sterilization, saliva was passed through a 0.22-HIm Millex-GV filter (Millipore Products Div., Bedford, MA). Submandibular secretions were collected using sterile collection devices (6, 7) and were size fractionated by gel filtration chromatography (D. Hay, Forsyth Dental Center, Boston, MA), using TrisAcryl Plus GF2000-M (Sigma Chemical Co., St. Louis, MO) in 100 mM ammonium bicarbonate, 0.1% chloroform. Fractions were lyophilized, reconstituted to the original starting volume of whole saliva with PBS, and assayed for anti-HIV-1 activity. Individual saliva-derived proteins included two closely related acidic proline-rich proteins, PRP-1 and PIF, statherin (gifts from D. Hay), purified histidine-rich peptides 3 and 5 (HRP-3 and HRP-5), partially purified lysozyme (Sigma Chemical Co. and gift from J. Pollock, Stony Brook, NY), lactoferrin (Sigma Chemical Co.), and cystatin (Sigma Chemical Co. and gift from T. Lah, Ljubljana, Slovenia). Synovial fluid was collected aseptically from the joints of patients with rheumatoid arthritis (22) .
Recombinant SLPI (23) was > 98% pure and contained < 0.74 endotoxin units per mg of SLPI. Recombinant SLPI and native SLPI are equivalent based on several criteria. In particular, they have the same amino-terminal sequence (H2-N-Ser-Gly-Lys-Ser-Phe-. . .) due to the activity of processing enzymes in Escherichia coli that remove the encoded methionine residue from the amino terminus. In addition, both recombinant and natural SLPI are not glycosylated.
HIV-I infection of monocytes. HIV-1BaL (Advanced Biotechnologies Inc., Columbia, MD), propagated in primary human monocyte/ macrophages, was diluted to 104 TCID50/ml of DME and combined in a 1:1 ratio with human saliva, serum, synovial fluid, or purified saliva proteins. The virus was incubated in the absence or presence of candidate inhibitory factors for 30 min at room temperature followed by 30 min at 37°C, 5% CO2. In some experiments, saliva was prefiltered through a sterile 0.22-pm filter before addition to virus. Alternatively, the virus/ unfiltered saliva suspension was incubated for 1 h and then filtered (postfiltered) through a 0.22-.tm filter, before being added to cells. The virus±inhibitor was added to adherent monocytes in two-well chamber slides, 400 1I per well. After 60 min at 37°C in 5% C02, unbound virus was removed by washing cells three times with 2 ml of PBS. Cells were refed with 2 ml of DME containing 10% human AB -serum, 50 ,ug/ml gentamicin, and 2 mM L-glutamine (DME complete medium).
In some experiments, monocytes were preincubated with candidate inhibitor for 1 h at 37°C, washed three times with PBS, and incubated with HIV-lBaL alone for 1 h at 37°C, and unbound virus was removed by washing cells three times with PBS. In all cases, every 3-4 d, 0.5 ml of medium was removed for virus assay and replaced with fresh complete medium. Cells were cultured for 3-3.5 wk after infection. When the infection time course was complete, slides were stained with Diff-Quik (Baxter Healthcare Corp., Miami, FL) to monitor whether equivalent numbers of monocytes remained in each well. Cell culture conditions and infection typically did not affect monocyte viability. However, data are reported only from experiments in which equivalent cell numbers were documented.
Isolation ofTcells and infection with HIV-I,,B. Primary T cells were separated from B cells and monocytes by countercurrent centrifugal elutriation (21) . T cells were cultured at 106 cells per ml in RPMI 1640 (BioWhittaker), 10% FCS (BioWhittaker), 2 mM L-glutamine, and 50 pg/ml gentamicin (RPMI complete medium), containing 50 pM [.3-mercaptoethanol and 5 pg/ml Con A. After 72 h at 370C, 5% CO2, the proliferating cells were infected with HIV-1m (Advanced Biotechnologies, Inc.), a T cell isolate (HIV-1Ba L does not infect T cells efficiently in vitro, therefore a T cell tropic strain must be used). HIV-1lIIB was first preincubated with SLPI or with medium only, for 1 h at 37TC, and the virus±SLPI (2 x 103 TCID50 of HIV-1mB) was used to infect T cells at 107 cells per ml in RPMI. After 1 h at 370C, 5% C02, T cells were pelleted and washed with PBS three times. Cells were resuspended in RPMI complete medium containing 20 U/ml LL-2 (Collaborative Biomedical Products, Bedford, MA) at 106 cells per ml in 48-well plates, and cell culture supernatants were sampled for the presence of RT activity or p24 antigen every 3-4 d.
Monitoring of viral infection. The RT assay was performed as described (24) . RT (25) .
Labeling of cell surface antigens. Single-cell suspensions (50 p1) of monocytes (107/ml) in PBS (with 0.1% NaN3) were incubated at 4°C for 30 min with FITC-conjugated monoclonal antibodies to the following cell surface antigens: IL-2 receptor (IL-2R), CD14, and CD4 (Becton Dickinson Monoclonal Center Inc., Mountain View, CA), or the control antibody, mouse FITC-IgG (Simultest; Becton Dickinson). Cells were stained in the presence of 10% human AB -serum to prevent nonspecific binding. After staining, cells were washed two times with cold PBS and resuspended in 0.5 ml of 2% paraformaldehyde. Cells were analyzed by flow cytometry with a FACScan (Becton Dickinson) (25) .
Proliferation assays. The continuous T cell line H9 was used to assess the potential cytostatic/cytotoxic effect of saliva and SLPI on cell proliferation. H9 cells were combined with whole saliva (diluted as for anti-HIV-l assay) for 1 h, washed three times with PBS, and plated at 105 cells per 200 pl per well in 96-well plates. Alternatively, SLPI (100 tg/ml) was added to H9 cells and left for the remainder of the proliferation time course (3 d Direct binding measurements to SLPI. SLPI binding to various proteins was assayed by surface plasmon resonance detection using a biospecific interaction analysis (BlAcore) instrument (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) (26) (27) . SLPI was immobilized on the CM5 sensor chip surface using the amine coupling kit containing N-hydroxysuccinimide (NHS), N-ethyl-N '-(3-diethylaminopropyl)-carbodiimide (EDC), and ethanolamine hydrochloride, pH 8.5 (Pharmacia LKB Biotechnology Inc.). Briefly, the carboxylated dextran matrix of the chip was activated with EDC/NHS for 7 min followed by the injection of 20 Ag/ml SLPI in 10 mM sodium acetate, pH 4.0, for 10 min. Unreacted NHS-ester groups were displaced by the injection of ethanolamine for 6 min. To assess the binding activity of the immobilized SLPI, 100 nM human neutrophil elastase (Calbiochem Corp., San Diego, CA) was injected at a flow rate of 10 ,d/min in 10 mM sodium Hepes, pH 7.0, 150 mM NaCl, and 3.4 mM EDTA. HIV-l protease (ITB), soluble (s)CD4, gpl60 (IIB), and gpl2O (IIIB) (all recombinant proteins were from American BioTechnologies, Inc., Cambridge, MA) were likewise used at concentrations of 100 nM. Recombinant gpl2O was also immobilized on the sensor chip surface, and sCD4 (20 ,og/ml) binding was measured using published methods (28).
Statistical analysis. Statistical analysis was performed using Stat View software (Abacus Concepts, Inc., Berkeley, CA) and choosing the one-way ANOVA and Fisher's protected least significant difference (PLSD) values for comparison of data pairs.
Results
Inhibition of monocyte infection after saliva treatment of HIV-1. As an initial investigation of the selective HIV-l-inhibiting activity of saliva, HIV-1 was incubated with saliva for 1 h, sterile filtered through a 0.22-,um pore filter, and added to adherent monocyte monolayers. After 1 h, both virus and saliva were washed off, and the progression of infection was monitored. As shown in Fig. 1 tant artificially reduced HIV-1 infection (8, (11) (12) (13) , additional experiments were conducted in which the saliva was prefiltered before it was added to the virus. Prefiltered saliva incubated with virus and not filtered again still significantly reduced monocyte infection, demonstrating the presence of a soluble factor in saliva with anti-HIV-1 activity (Fig. 2 A) . For comparison, two other protein-rich body fluids, plasma and synovial fluid, were added to HIV-1, incubated, and added to the monocytes in parallel with filtered saliva. Whereas the saliva inhibited HIV-1 by 85-95%, no inhibitory activity was observed in either plasma or synovial fluid (Fig. 2 B) , indicating that a unique antiviral molecule(s) is present in saliva.
Investigation of saliva components for anti-HIV-I activity. To investigate the properties of the soluble factor(s) responsible for the HIV-1-inhibiting activity of saliva, 20 ml of stimulated submandibular saliva was subjected to fractionation by gel filtration. The low molecular weight (between 10 and 14 kD) protein-enriched fractions were found to contain the antiviral activity, as measured by their ability to inhibit HIV-1 infection of monocytes (data not shown).
In parallel experiments, purified and recombinant components of whole saliva associated with these fractions were individually examined directly for antiviral activity. Representatives of the four major classes of saliva proteins were assayed: the proline-rich proteins (PRP-1 and PEF), the histatins (HRP-3 and HRP-5), statherin, and cystatin, some of which have antifungal as well as antibacterial activities (29) . Several host defense proteins found in saliva, including lysozyme, lactoferrin, and SLPI, were also assayed. When assayed at levels exceeding physiological concentrations, PRP, statherin, and HRP had minimal or no anti-HIV-l activity (Table I) Control DUEM Suilve 311wo
Control DUEM S311v Pliasm Sr (Pro) (Post) (Pro) when assayed at levels exceeding saliva concentrations by 10-20-fold (Table I) (Table I) . SLPI inhibition of HIV-1 in monocytes. As shown in Fig.  3 , recombinant SLPI was able to duplicate the anti-HIV-1 activity of whole saliva based on RT assays, and a single exposure to SLPI at the time of coculture of monocytes and HIV-1 suppressed infection for nearly 3 wk of culture. Viral p24 antigen was measured to confirm RT assay results, and that assay gave results similar to RT assays (Fig. 3 B) . To confirm the RT and (Fig. 4 A) .
SLPI inhibition of HIV-I in T cells. SLPI also exhibited partial anti-HIV-1 activity in proliferating T cells, with a doseresponse curve similar to that observed in adherent monocytes (Fig. 4 B) . In these experiments, SLPI was added to the T cells only during the initial viral exposure and was washed off before cell culture. Repetitive administration of SLPI to these proliferating cell populations would likely maintain viral suppression.
Examination of the anti-HIV-I activity of SLPL the anti-HIV-1 activity of saliva, whole saliva was partially depleted of SLPI and compared with a control whole saliva sample (both were prepared as described in Methods). These intact and SLPI-deficient saliva samples were incubated with HIV-1 and monocytes infected as described previously. Approximately 50% of the SLPI could be removed from the sample when passaged through the anti-SLPI column, as monitored by radiolabeled SLPI and by Western analysis (Fig. 5 B) . However, by Coomassie blue staining of proteins analyzed on SDS-PAGE, all other saliva proteins remained equivalent in concentration to those in the intact control sample (Fig. 5 C) . This selective removal of SLPI decreased the anti-HIV-1 activity of the saliva sample compared with the control sample (Fig. 5 A). The anti-HIV-1 activity of saliva partially depleted of SLPI was reduced by 48% compared with intact saliva when used at a dilution of 1:10 during monocyte infection, consistent with the 50% depletion of the protein. Thus, although other saliva constituents may also contribute to the antiviral activity of saliva, it is clear that SLPI accounts for a major portion of the anti-HIV-l activity in intact saliva. Examination of the SLPI-target molecule interaction. The question of whether SLPI influences viral infection by influencing viral activity or the host cells was investigated. SLPI (10 ,ug/ml) was preincubated with adherent monocytes for 1 h and then washed away before the 1-h viral addition. Significantly, SLPI exhibited equivalent antiviral activity under these conditions, as in experiments in which SLPI was preincubated with virus before addition to monocytes (> 90% inhibition of RT values assayed at 16-20 d after infection), suggesting that its target resides at the level of the host cell rather than the virus. Under the conditions of this experiment, it was determined by SLPI ELISA (R & D Systems, Inc., Minneapolis, MN) that only 2-20 ng/ml of SLPI remained free in the culture supernatant after aspiration of the culture supernatant and washing the cells three times with PBS. In a second set of experiments, highly concentrated virus stock (TCID5o = 0.5 X 10750/ml) was incubated with 5 ttg/ml SLPI or DME only, for 1 h at 37TC. The virus was then diluted (TCIDIo = 6.3 X 104/ml) and used to infect monocytes as usual. The final concentration of SLPI with the virus during infection was 0.02 Ag/ml, which is below the level at which SLPI significantly inhibits HIV-1 infectivity. The virus preincubated with SLPI and then diluted gave the same level of infection (RT = 12.8 X 104+l.4 X 104 cpm at day 21) as the virus preincubated with medium alone (RT = 13.8 X 104±4.9 X 104 cpm). It thus appeared that SLPI's target is cell, not virus, associated.
To extend this analysis and investigate potential binding sites on the virus and cells, the BlAcore system was used to measure the binding of SLPI to specific candidate molecule targets on the virus or host cell. When the viral proteins HIV-1 protease, gpl6O, and gpl2O (all at 100 nM) were tested, no specific binding of any of these viral constituents to immobilized SLPI was observed (Fig. 6) identical conditions, however, immobilized SLPI was capable of binding human neutrophil elastase (Fig. 6 ), reflecting its biological activity in solution (20) . In control experiments, to ensure that the viral recombinant proteins maintained biological binding activity, the binding activities of the recombinant sCD4 and gpl2O were examined using the BlAcore system. The observed binding of sCD4 to immobilized gpl20 (data not shown) was consistent with published results (28). Therefore, the evidence indicates that the SLPI anti-HIV-1 activity is most likely due to an interaction with a host cell molecule and not a direct interaction with virus particles. Importantly, the host cell molecule does not appear to be CD4.
Discussion
The virtual absence of HIV-1 spread via oral transmission suggests the presence of an important natural anti-HIV-l agent(s) in the oral cavity (1) (2) (3) (4) . Indeed, even the isolation of intact virus from saliva of AIDS patients is exceedingly rare (30) (31) . Although nonspecific antiviral activity may be found in other body fluids (14, 32, 33) , antiviral activity specific for HIV-1 has thus far been described only in salivary gland secretions. In this study we demonstrate that the anti-HIV-1 activity of whole saliva can be attributed, at least in part, to the 12-kD polypeptide, SLPI, found in saliva at microgram concentrations Figure 6 . Biosensor-derived binding curves for the injection of (1) HIVprotease, (2) human neutrophil elastase (HNE), (3) sCD4, (4) gpl20, (5) gpl6O, and (6) (34). Depletion of SLPI from intact saliva resulted in a corresponding loss of antiviral activity, confirming that SLPI represents a major portion of the anti-HIV-1 activity in saliva.
SLPI is a serine protease inhibitor produced by salivary glands and is found in saliva and other mucous secretions. The protein consists of two homologous cysteine-rich domains and exhibits inhibitory activity against neutrophil elastase, chymotrypsin, trypsin, and cathepsin G (20, 35) . By site-directed mutagenesis, residue has been shown to be the active site for SLPI's protease inhibitory activity (22) . It is this antiprotease activity that led to preclinical and clinical studies using SLPI in emphysema and cystic fibrosis patients (36, 37) , but this is the first evidence that SLPI has antiviral activity.
SLPI was found to inhibit HIV-1 infectivity of monocytes and T lymphocytes in a dose-dependent manner, with significant inhibition observed at a concentration as low as 0.1 gg/ml (8 nM) and maximally at 1-10 IOug/ml, well within the physiologic range. As demonstrated by both RT and p24 levels, a single 1-h exposure to SLPI during infection was sufficient to suppress virus production for several weeks. Ultrastructural analysis confirmed RT and p24 assay results, demonstrating that virus was not being routed to and accumulating in an abnormal compartment within the cells, such that it could not be assayed in the culture supernatant.
Based on the profound antiviral activity of SLPI, efforts were directed at defining its mechanism of action and whether its target resided at the level of the virus or the cell being infected. Several lines of evidence suggest that SLPI interacts with cell-associated molecules to effect its antiviral actions. First, that SLPI need not interact directly with virus particles to exhibit antiviral activity was demonstrated by results showing that preincubation of monocytes with SLPI alone, before addition of virus, was sufficient to inhibit HIV-1 infectivity. The ability to pretreat cells with SLPI and induce inhibition of HIVinfection implicated the cells, rather than the virus, as the target of SLPI's action. Second, in related experiments, when concentrated HIV-1 was coincubated with high levels of SLPI that were then diluted to noninhibitory levels before infection, no suppression or inhibition of the virus was observed. Third, SLPI was not found to bind specifically to the viral surface proteins gpl6O or gpl2O, nor to HIV-1 protease.
Experiments to identify the cell-associated molecules, or targets, for SLPI's anti-HIV-l activity suggest that specific binding of SLPI to sCD4 does not occur; nor does SLPI downregulate the CD4 antigen on monocytes. Although we cannot rule out the possibility that SLPI forms a complex with CD4 and an as yet unidentified molecule, our data suggest other cell-associated interactions may be involved. It has been well documented that HIV-1 entry into host cells requires more than viral binding to cell CD4 antigen (38) (39) (40) (41) . Evidence has been presented suggesting involvement of a cell surface enzyme(s) in the infection of CD4+ cells by HIV-1. The enzyme may be a protease (40, (42) (43) (44) or protein disulfide-isomerase (45) , and it is possible that SLPI competes for binding with the virus for a cell surface enzyme(s). A subpopulation of PBMC express both cathepsin G and human neutrophil elastase (46) , which are susceptible to SLPI activity. Interestingly, cathepsin G, a target enzyme of SLPI (20) , has been identified as a cell surface protease on U937 cells that interacts specifically with the V3 loop of HIV-1 gpl2O (47) . However, the anti-HIV-1 activity of SLPI is not a general property of proteinase inhibitors, since plasma, which contains high levels of several proteinase inhibitors (e.g., alpha-1 protease inhibitor and alpha-2 macroglobulin), does not exhibit anti-HIV-1 activity. SLPI is positively charged and may bind to the surface of cells nonspecifically via electrostatic interactions. However, it is unlikely that this could lead to inhibition of HIV, since only anionic compounds have been reported to prevent HIV's binding to cells (e.g., dextran sulfate, heparin, etc.) (48, 49) , and moreover, SLPI's interaction with monocytes reflects specific, high affinity binding (McNeely, T. B., manuscript in preparation). In addition, lysozyme is also highly positively charged and does not exhibit the potent antiviral activity of SLPI (Table I) . Therefore, SLPI most likely exhibits its antiviral activity by binding specifically to a host cell molecule(s) other than the HIV-1 receptor, CD4. Administration of SLPI to humans or sheep has been shown to cause an increase in glutathione (GSH) levels in pulmonary lining fluid (50) , presumably mediated by host cells, and furthermore, it has been well established that intracellular GSH can inhibit the growth of HIV-1 by blocking proviral transcription and possibly other processes required for viral propagation (51, 52) . Whether this pathway plays any role in SLPI's antiviral activity in vitro is currently unknown. Studies in progress will provide insight as to whether SLPI's anti-HIV-1 activity is the result of inducing higher intracellular GSH levels in human monocytes, SLPI antiprotease activity, or some as yet to be identified mechanism.
In the current studies, SLPI was shown, for the first time, to contribute to the anti-HIV-1 activity of human saliva in vitro; thus, it may play an important role in the unique anti-HIV-1 infectivity activity of human saliva. It is currently unknown whether SLPI functions as an anti-HIV-1 agent in other tissues of the body, although SLPI is generally present at higher concentrations in tissues associated with lower rates of transmission of HIV-1 (34, (53) (54) (55) . If an inverse correlation exists between levels of SLPI and the risk or rate of HIV-1 transmission, exogenously administered SLPI may afford protection against this lethal virus.
